The number of people infected with the new coronavirus continues to skyrocket, with more than 80,000 cases worldwide as of
Continue reading »Home ยป
Nivolumab combined with ipilimumab safe as first-line therapy for lung cancer patients
Combining the PD-1 immune check point inhibitor nivolumab with the monoclonal antibody ipilimumab showed a consistent safety profile in special
Continue reading »BioSight Launches a Phase 2b Clinical Trial of BST-236 as a First-Line Treatment of Acute Myeloid Leukemia
AIRPORT CITY, Israel, July 11, 2018 /PRNewswire/ — BioSight Ltd., a pharmaceutical development company focused on the development of targeted
Continue reading »